Midterm Results Put FDA AI Device Oversight and Healthcare Reimbursement at Stake

The Democratic midterm sweep did not just reshape the federal AI policy debate — it placed two specific healthcare AI priorities back on the legislative calendar after years of stall. According to STAT News, incoming Democratic committee leadership is expected to move quickly on FDA authority over AI medical devices and federal reimbursement pathways for AI-assisted care — the two issues that most directly affect whether AI tools reach patients or remain perpetually in clinical limbo.

Both issues have been blocked in the outgoing Congress, leaving a critical regulatory gap: the FDA has cleared 1,357 AI-enabled medical devices, but the legislative authority governing how those devices are reviewed, updated, and reimbursed has not been updated since most of them were approved.

The FDA Authority Problem

AI-enabled medical devices present a category problem for the FDA's existing regulatory framework. Traditional medical devices are cleared once and then largely static. An AI diagnostic tool — a radiology algorithm that learns from new data, a sepsis prediction model that retrains quarterly — changes over time. The FDA's current framework, designed for static devices, requires reapproval or supplemental clearance for certain types of modifications, but the guidance is ambiguous and enforcement has been inconsistent.

The result is a 1,357-device portfolio of cleared AI tools operating under rules that were never designed for them. Some developers have been conservative, locking their models to avoid triggering reapproval requirements. Others have continued updating with minimal oversight. Neither approach is what a coherent regulatory framework would produce.

Democrats on the House Energy and Commerce Committee have backed the Healthy Technology Act and similar proposals that would give the FDA explicit authority to require transparency about AI model updates and establish a continuous performance monitoring standard for cleared AI devices. That legislation stalled under the outgoing Congress but is now a likely early-session priority.

The Reimbursement Gap

Even cleared AI tools face a barrier that has nothing to do with FDA approval: Medicare and Medicaid do not have systematic reimbursement codes for AI-assisted care. A hospital can deploy an AI tool that reduces readmissions or improves diagnostic accuracy, but if the AI component of a clinical encounter is not reimbursable, the economics do not work for most health systems.

The Centers for Medicare and Medicaid Services (CMS) has created a small number of AI-specific reimbursement codes on an ad hoc basis — the ambient AI scribe rollout at the VA is partly enabled by specific coding accommodations — but there is no systematic framework. Health AI developers consistently cite reimbursement uncertainty as a primary reason clinical AI adoption has lagged behind development.

The consequence: A clinical AI tool that works, is FDA-cleared, and demonstrably improves outcomes can still fail commercially because there is no payment mechanism. That creates a gap between AI innovation and patient access.

Incoming committee leadership has signaled interest in directing CMS to establish a formal AI reimbursement pathway — either through the annual Medicare payment rules process or dedicated legislation — as part of a broader healthcare AI package.

State Sandbox Frameworks as a Bridge

One area where industry watchers expect faster movement is state-level AI health sandboxes. Several states, including Utah and California, have created or proposed controlled environments where AI health tools can be used under regulatory supervision outside full FDA clearance pathways. Democrats have been supportive of these frameworks as a way to accelerate access while federal standards develop.

The incoming Congress is expected to explore federal legislation that would enable and standardize state health AI sandboxes — creating a pathway for tools that are too novel for existing FDA categories to reach patients in supervised settings while longer-term regulatory frameworks are built.

What This Means for Healthcare AI Companies

For developers of cleared AI medical devices, the near-term policy trajectory means greater scrutiny on model update practices. Developers who have been updating AI tools without clear FDA notification may face retroactive compliance review if the Healthy Technology Act passes.

For health systems and hospitals, a federal reimbursement pathway changes the ROI calculation for AI deployment significantly. Tools that currently cannot be justified financially because the AI component generates no billable revenue become viable once CMS establishes payment codes.

For the broader health AI investment market, congressional movement on reimbursement is the most significant near-term catalyst. The $1.5 billion Astrazeneca-Insitro deal and the growing clinical AI portfolio at companies like GE Healthcare are predicated on eventually clearing the reimbursement barrier. Legislation that addresses it accelerates the entire sector's commercial timeline.

What to Watch

Watch for the composition of the House Energy and Commerce Committee's health subcommittee in January 2027. The chair of that subcommittee will control the legislative calendar for both FDA AI authority and reimbursement pathway proposals. Early hearings scheduled for February or March would signal these priorities are being treated as urgent rather than aspirational.